

Dividing cancer cell

Newly diagnosed metastatic prostate cancer: Treatment options of today

November 17th, 2020 | 17.30-18.30 h | Virtual symposium

PREFACE

Welcome!

Since the publication of the CHAARTED trial in 2015 where the early use of chemotherapy with docetaxel in patients with metastatic hormone-sensitive prostate cancer has led to an overall survival benefit the landscape has changed dramatically. Several new agents have shown similar results and in selected patients also radiation therapy of the primary tumour. For abiraterone/prednisone and apalutamide the study results already led to approval in this indication. The trials have however included different patient populations and used a number of definitions for the disease classification. When counselling patients with metastatic hormone-sensitive prostate cancer a number of variables need to be taken into considerations. This symposium will give an overview and include interactive patient cases.

PD Dr. med. Aurelius Omlin
Oncology,
Cantonal Hospital St. Gallen (KSSG)

Prof. Dr. Dr. Daniel Eberli
Urology,
University Hospital Zurich (USZ)

PROGRAM

Newly diagnosed metastatic prostate cancer: Treatment options of today

Tuesday, November 17th, 2020 | 17.30-18.30 h
Virtual symposium (Link for login will be sent after registration)

17:15-17:30 h	**Dial-in**
17:30-17:45 h	**How to treat my mHSPC patient: Case discussions** Prof. Dr. Dr. D. Eberli
17:45-18:10 h	**Newly diagnosed metastatic prostate cancer: How to choose between the treatment options?** PD Dr. A. Omlin
18:10-18:30 h	**Discussion (incl. patient cases)** Prof. Dr. Dr. D. Eberli, PD Dr. A. Omlin

This symposium is CME accredited by SGMO and SGU (1 CME credit each).

Watching the webinar on-demand:

The symposium will be recorded and can be watched on-demand until December 16, 2020.
Please register for the live webinar to get access to the on-demand version.

During the live webinar you will have the chance to ask questions and interactively discuss the patient cases.

This symposium is only CME accredited for the live participation.

CH_EM-42680

This symposium is supported by:

Co-Sponsor: